Drug Trial Radar · NCT05111002
Lefamulin for M. Genitalium Treatment Failures
Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
12
Actual
Start
Apr 22, 2022
Primary completion
Nov 30, 2023
Study completion Nov 30, 2023
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nabriva Therapeutics AG
- First posted
- Nov 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this drug study is to find out whether the antibiotic lefamulin (trade name Xenleta) will cure Mycoplasma genitalium infections that have not been cured by prior antibiotics while finding out whether it is more effective if the antibiotic doxycycline is taken first.
Conditions
- Mycoplasma Genitalium Infection
Interventions
LefamulinDrug
600mg tablet orally twice daily
DoxycyclineDrug
100mg tablet orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and Percentage of Participants With Microbiologic CureTime frame: 21-28 days after completion of the lefamulin
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.